sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÂýÐÔÉöË¥½ßÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > ÂýÐÔÉöË¥½ßÄ£×Ó

ǰÑÔ

ÂýÐÔÉöË¥½ß(chronic renal failure,CRF)ÊÇÔÚ¶àÖÖÉöÔàʵÖÊÐÔ¼²²¡µÄ»ù´¡ÉÏ£¬ÓÉÉöʵÖÊËðº¦ÒýÆðµÄ»ºÂý¾ÙÐÐÐÔÉöË¥½ß£¬Ê¹ÌåÄÚµªÖʼ°Æä´úлÎïäóÁô£¬µç½âÖʺÍËá¼îƽºâÔÓÂÒ¡£Í¨³£ÔÚÏ൱³¤µÄʱ¼äÄÚÉöСÇòÂ˹ýÂÊÒÑÏÔ×ÅϽµ£¬ÌåÏÖΪѪÐé¡¢Ò¹Äò£¬ÑªÇåCr¡¢BUN¡¢ÑªÁ×Éý¸ß£¬Ñª¸ÆÏ½µºÍË«²àÉöÌå»ýËõСµÈ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÏÙàÑßÊͨ¹ý»ÆàÑßÊÑõ»¯Ã¸µÄ×÷ÓÃÌìÉú2,8-¶þôÇ»ùÏÙàÑßÊ£¬ºóÕß³Á»ýÓÚÉöСÇòÓëÉö¼äÖʲ¿Î»£¬ÐγÉÒìÎïÈâÑ¿Ö×ÐÔÑ×Ö¢£¬²¢¹£ÈûÉöС¹ÜÇ»ÒýÆðÏìÓ¦µÄÉöС¹ÜÇ»ÁÑ×´À©ÕÅ¡£Ë没³ÌÏ£Íû£¬Éöµ¥Î»´ó×ÚËðʧµ¼ÖÂÉöË¥½ß¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

Ñ¡ÓÃÌåÖØ(200±30)gÐÛÐÔWistar´óÊó£¬ÓÃͨË×ËÇÁÏËÇÑø1Öܺó¡£½«ÏÙàÑßÊ1gÈÜÓÚ40mlÐÄÀíÑÎË®ÖÐÖÆ³É»ìÐüÒº£¬Å¨¶ÈΪ2.5%£¬°´200mg/(kg·d)¼ÁÁ¿£¬ÖðÈÕ׼ʱ¸ø´óÊó¹àθ¸øÒ©£¬Ò»Á¬24Ì졣ʵÑéºóÕý·¨¶¯ÎȡÉö×éÖ¯10£¥¼×È©Àο¿£¬Ê¯À¯°üÂñ£¬ÇÐÆ¬£¬H&EȾɫ£¬×ö¹â¾µ²¡Àí×é֯ѧ¼ì²é²¢ÉãÆ¬¡£

¡¾Ä£×ÓÌØµã¡¿£º

ÉöË¥½ßÌåÏֵ䷶£¬ÓÐÏÔ×ÅÌåÕ÷¡£Ä£×Ó×é´óÊóËæ¸øÏÙàÑßÊÌìÊýµÄÔöÌí¶øÈÕ½¥ÏûÊÝ£¬Î·º®Ö«Àä¡¢òéËõ¹­±³¡¢¾«ÉñήÃÒ¡¢ÌåëÍÑÂ䡢ˮÖ×±ãäç¡¢ÉöÔà³Ê“Ã÷È·Éö£¢£¬ºìϸ°û¡¢ÑªºìÂѰ׽µµÍ£¬BUN¡¢CrÉý¸ß£¬µÍ¸Æ¸ßÁ×£¬·ºÆðÂýÐÔÉöË¥½ßÖ÷ÒªÉú»¯¸Ä±ä¡£ÉöС¹Ü²¡Àíѧ¸Ä±äÏÔ×Å£¬ÏÙàÑßÊÓÕµ¼µÄCRFÄ£×Ó±¬·¢ÉöС¹Ü¹£Èû£¬²¡Àí¸Ä±äÖ÷ҪΪÉöС¹ÜË𺦡£ÉöÔàÏÔ×ÅÔö´ó£¬Á½Éö³Ê»Ò°×É«£¬Íâò¿ÅÁ£×´£¬Éö°üĤÓëÉöʵÖÊÕ³Á¬²»Ò×°þÀ룬ÇÐÃæÆ¤ËèÖʷֽ粻Çå¡£¹â¾µÏ£¬ÉöСÇòÊýÄ¿ïÔÌ­£¬³ÊήËõ×´£¬ÐÎ̬»ù±¾Õý³£¡£ÉöС¹ÜÄÒ×´À©ÕÅ£¬ÉöƤÖÊÆÕ±é½á¾§³Á»ý£¬½á¾§ÖÜΧ¿É¼ûÒìÎï¾Þϸ°û·´Ó¦£¬´ó×ÚÉöС¹ÜÆÆËð¡¢Î®ËõÏûÊÅ¡£ÓÐÑ×֢ϸ°û½þÈ󣬼äÖÊÏËά»¯ÏÔ×Å¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

´óÊóÏÙàÑßÊCRFÄ£×ÓÒªÁìÇáÓ¯¿É¿Ø£¬¿Éƾ֤ÏÙàÑßʼÁÁ¿µÄ¾ÞϸºÍÎ¹ÑøÊ±¼äµÄÊÇ·ÇÖÆ×÷³ÉÇá¡¢ÖС¢ÖضȵÄÉöË¥½ßÄ£×Ó£¬²¡³ÌÎȹÌ£¬ÏàÒ˺ã¾Ã¸øÒ©£¬ÀÖ³ÉÂʸߣ¬Ò×ÓÚÍÆ¹ãÓ¦Óᣲ¡ÀíѧÊÓ²ìÅú×¢£¬´ËÄ£×ÓÒÔÉöС¹ÜÆÆËðΪÖ÷ÒªÌØÕ÷£¬¾ßÓлָ´ÉöС¹Ü¹¦Ð§µÄÐÂÒ©ÓôËÄ£×ÓÒ×·ºÆðÑôÐÔ½á ¹û¡£¾Ý±¨µÀ£¬´ËÄ£×Ó»¹ÄÜʹ¶¯Îï»ù´¡ÌåνµµÍ£¬ØºÍè×é֯ήËõ£¬¾«×ÓïÔÌ­£¬½üÄêÀ´¶à×÷Ϊ£¢ÉöÑôÐé“Ä£×ÓʹÓã¬ÒÔÊǾßÓÐÎÂÉö¹¦Ð§µÄ¿¹ÉöË¥ÐÂÒ©ÓôËÄ£×Ó¸üΪÊʺÏ¡£

 

²Î¿¼ÎÄÏ×£º

1.ÁõÏ裬ÕŰ×Óñ£¬ÍõÈÙ£®ËÄÖÖ¼±ÐÔÉöË¥½ßÄ£×ÓµÄÖÆ×÷ÓëÌå»á£®ÊµÑ鶯Îï¿ÆÑ§£¬2009,26(4):16-19

2.ɳ³¯êÍ£¬¸¶Æ½£¬ÖÜÀò£¬µÈ£®´óÊó5/6ÉöÇгýÂýÐÔÉöË¥½ß¶¯ÎïÄ£×ÓµÄʵÑéÑо¿£®ËÄ´¨¶¯Î2006, 25 (3):632-635

3.Öܾ²£¬°®Ãñ£¬ÍõÏòÑô£¬µÈ£®ÏÙàÑßÊÖÆ×÷ÂýÐÔÉöË¥½ß´óÊó¼²²¡Ä£×Ó£®ÄÚÃɹÅҽѧԺѧ±¨£¬2004,26 (4):248-249

4.ÕÔº£Ï¼. Ç嵪¹à³¦Òº¶ÔÏÙàÑßÊËùÖ´óÊóÂýÐÔÉöË¥½ßÄ£×ÓµÄÓ°Ï죮ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2004,5(11): 634-636

5.ÐìÓ¦³¼£¬ÕÅÐñ£¬ÕÅ´äÞ±£¬µÈ.L£­Èâ¶¾¼î¶ÔÇì´óÃ¹ËØÒýÆðµÄ¼±ÐÔÉöË¥½ßµÄ±£»¤×÷ÓÃÑо¿£®ÖйúÒ½Ò©µ¼±¨£¬2012, 9(7):28-29

6.Siegler RL,Pysher TJ,Tesh VL,et al. Response to single and divided doses of Shiga toxin in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol,2001, 12(7):1458-1467

7. Stockel man MG, Lorenz JN, Smith FN, el al. Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am J Physiol,1998,275 (1 Pt 2): F154-163

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > ÂýÐÔÉöË¥½ßÄ£×Ó
ÂýÐÔÉöË¥½ßÄ£×Ó

ǰÑÔ

ÂýÐÔÉöË¥½ß(chronic renal failure,CRF)ÊÇÔÚ¶àÖÖÉöÔàʵÖÊÐÔ¼²²¡µÄ»ù´¡ÉÏ£¬ÓÉÉöʵÖÊËðº¦ÒýÆðµÄ»ºÂý¾ÙÐÐÐÔÉöË¥½ß£¬Ê¹ÌåÄÚµªÖʼ°Æä´úлÎïäóÁô£¬µç½âÖʺÍËá¼îƽºâÔÓÂÒ¡£Í¨³£ÔÚÏ൱³¤µÄʱ¼äÄÚÉöСÇòÂ˹ýÂÊÒÑÏÔ×ÅϽµ£¬ÌåÏÖΪѪÐé¡¢Ò¹Äò£¬ÑªÇåCr¡¢BUN¡¢ÑªÁ×Éý¸ß£¬Ñª¸ÆÏ½µºÍË«²àÉöÌå»ýËõСµÈ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÏÙàÑßÊͨ¹ý»ÆàÑßÊÑõ»¯Ã¸µÄ×÷ÓÃÌìÉú2,8-¶þôÇ»ùÏÙàÑßÊ£¬ºóÕß³Á»ýÓÚÉöСÇòÓëÉö¼äÖʲ¿Î»£¬ÐγÉÒìÎïÈâÑ¿Ö×ÐÔÑ×Ö¢£¬²¢¹£ÈûÉöС¹ÜÇ»ÒýÆðÏìÓ¦µÄÉöС¹ÜÇ»ÁÑ×´À©ÕÅ¡£Ë没³ÌÏ£Íû£¬Éöµ¥Î»´ó×ÚËðʧµ¼ÖÂÉöË¥½ß¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

Ñ¡ÓÃÌåÖØ(200±30)gÐÛÐÔWistar´óÊó£¬ÓÃͨË×ËÇÁÏËÇÑø1Öܺó¡£½«ÏÙàÑßÊ1gÈÜÓÚ40mlÐÄÀíÑÎË®ÖÐÖÆ³É»ìÐüÒº£¬Å¨¶ÈΪ2.5%£¬°´200mg/(kg·d)¼ÁÁ¿£¬ÖðÈÕ׼ʱ¸ø´óÊó¹àθ¸øÒ©£¬Ò»Á¬24Ì졣ʵÑéºóÕý·¨¶¯ÎȡÉö×éÖ¯10£¥¼×È©Àο¿£¬Ê¯À¯°üÂñ£¬ÇÐÆ¬£¬H&EȾɫ£¬×ö¹â¾µ²¡Àí×é֯ѧ¼ì²é²¢ÉãÆ¬¡£

¡¾Ä£×ÓÌØµã¡¿£º

ÉöË¥½ßÌåÏֵ䷶£¬ÓÐÏÔ×ÅÌåÕ÷¡£Ä£×Ó×é´óÊóËæ¸øÏÙàÑßÊÌìÊýµÄÔöÌí¶øÈÕ½¥ÏûÊÝ£¬Î·º®Ö«Àä¡¢òéËõ¹­±³¡¢¾«ÉñήÃÒ¡¢ÌåëÍÑÂ䡢ˮÖ×±ãäç¡¢ÉöÔà³Ê“Ã÷È·Éö£¢£¬ºìϸ°û¡¢ÑªºìÂѰ׽µµÍ£¬BUN¡¢CrÉý¸ß£¬µÍ¸Æ¸ßÁ×£¬·ºÆðÂýÐÔÉöË¥½ßÖ÷ÒªÉú»¯¸Ä±ä¡£ÉöС¹Ü²¡Àíѧ¸Ä±äÏÔ×Å£¬ÏÙàÑßÊÓÕµ¼µÄCRFÄ£×Ó±¬·¢ÉöС¹Ü¹£Èû£¬²¡Àí¸Ä±äÖ÷ҪΪÉöС¹ÜË𺦡£ÉöÔàÏÔ×ÅÔö´ó£¬Á½Éö³Ê»Ò°×É«£¬Íâò¿ÅÁ£×´£¬Éö°üĤÓëÉöʵÖÊÕ³Á¬²»Ò×°þÀ룬ÇÐÃæÆ¤ËèÖʷֽ粻Çå¡£¹â¾µÏ£¬ÉöСÇòÊýÄ¿ïÔÌ­£¬³ÊήËõ×´£¬ÐÎ̬»ù±¾Õý³£¡£ÉöС¹ÜÄÒ×´À©ÕÅ£¬ÉöƤÖÊÆÕ±é½á¾§³Á»ý£¬½á¾§ÖÜΧ¿É¼ûÒìÎï¾Þϸ°û·´Ó¦£¬´ó×ÚÉöС¹ÜÆÆËð¡¢Î®ËõÏûÊÅ¡£ÓÐÑ×֢ϸ°û½þÈ󣬼äÖÊÏËά»¯ÏÔ×Å¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

´óÊóÏÙàÑßÊCRFÄ£×ÓÒªÁìÇáÓ¯¿É¿Ø£¬¿Éƾ֤ÏÙàÑßʼÁÁ¿µÄ¾ÞϸºÍÎ¹ÑøÊ±¼äµÄÊÇ·ÇÖÆ×÷³ÉÇá¡¢ÖС¢ÖضȵÄÉöË¥½ßÄ£×Ó£¬²¡³ÌÎȹÌ£¬ÏàÒ˺ã¾Ã¸øÒ©£¬ÀÖ³ÉÂʸߣ¬Ò×ÓÚÍÆ¹ãÓ¦Óᣲ¡ÀíѧÊÓ²ìÅú×¢£¬´ËÄ£×ÓÒÔÉöС¹ÜÆÆËðΪÖ÷ÒªÌØÕ÷£¬¾ßÓлָ´ÉöС¹Ü¹¦Ð§µÄÐÂÒ©ÓôËÄ£×ÓÒ×·ºÆðÑôÐÔ½á ¹û¡£¾Ý±¨µÀ£¬´ËÄ£×Ó»¹ÄÜʹ¶¯Îï»ù´¡ÌåνµµÍ£¬ØºÍè×é֯ήËõ£¬¾«×ÓïÔÌ­£¬½üÄêÀ´¶à×÷Ϊ£¢ÉöÑôÐé“Ä£×ÓʹÓã¬ÒÔÊǾßÓÐÎÂÉö¹¦Ð§µÄ¿¹ÉöË¥ÐÂÒ©ÓôËÄ£×Ó¸üΪÊʺÏ¡£

 

²Î¿¼ÎÄÏ×£º

1.ÁõÏ裬ÕŰ×Óñ£¬ÍõÈÙ£®ËÄÖÖ¼±ÐÔÉöË¥½ßÄ£×ÓµÄÖÆ×÷ÓëÌå»á£®ÊµÑ鶯Îï¿ÆÑ§£¬2009,26(4):16-19

2.ɳ³¯êÍ£¬¸¶Æ½£¬ÖÜÀò£¬µÈ£®´óÊó5/6ÉöÇгýÂýÐÔÉöË¥½ß¶¯ÎïÄ£×ÓµÄʵÑéÑо¿£®ËÄ´¨¶¯Î2006, 25 (3):632-635

3.Öܾ²£¬°®Ãñ£¬ÍõÏòÑô£¬µÈ£®ÏÙàÑßÊÖÆ×÷ÂýÐÔÉöË¥½ß´óÊó¼²²¡Ä£×Ó£®ÄÚÃɹÅҽѧԺѧ±¨£¬2004,26 (4):248-249

4.ÕÔº£Ï¼. Ç嵪¹à³¦Òº¶ÔÏÙàÑßÊËùÖ´óÊóÂýÐÔÉöË¥½ßÄ£×ÓµÄÓ°Ï죮ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2004,5(11): 634-636

5.ÐìÓ¦³¼£¬ÕÅÐñ£¬ÕÅ´äÞ±£¬µÈ.L£­Èâ¶¾¼î¶ÔÇì´óÃ¹ËØÒýÆðµÄ¼±ÐÔÉöË¥½ßµÄ±£»¤×÷ÓÃÑо¿£®ÖйúÒ½Ò©µ¼±¨£¬2012, 9(7):28-29

6.Siegler RL,Pysher TJ,Tesh VL,et al. Response to single and divided doses of Shiga toxin in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol,2001, 12(7):1458-1467

7. Stockel man MG, Lorenz JN, Smith FN, el al. Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am J Physiol,1998,275 (1 Pt 2): F154-163

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿